New Genetic Discoveries and Treatment for Hepatitis C

Pacanowski, Michael; Amur, Shashi; Zineh, Issam
May 2012
JAMA: Journal of the American Medical Association;5/9/2012, Vol. 307 Issue 18, p1921
Academic Journal
The authors discuss the discovery of Chronic hepatitis-C (HC) pharmacogenetics and its use in future drug development in the U.S. They offer a background on the milestones in HC virus drug development. They also explore some studies on the relevance of the pharmacogenomic evolution in CHC, including the potential of the host IL28B gene as predictor of sustained virologic response after treatment with peginterferon alfa and ribavirin.


Related Articles

  • Prospect of Individualized Medicine in Chronic Hepatitis C Therapy by Pharmacogenomics. Yuchi Hwang; Chunli Su; Ding-Shinn Chen; Pei-Jer Chen // Current Pharmacogenomics;Jun2006, Vol. 4 Issue 2, p157 

    Interferon-α and ribavirin combination therapy has been the current choice for treating chronic hepatitis C (CHC) patients. The treatment takes 6 to 12 months but the overall sustained response rate is only around 50% and often brings significant adverse effects to some patients. The...

  • Review: Interferon-α plus ribavirin improves the virologic response in chronic hepatitis C. Reichen, Juerg // ACP Journal Club;Jul/Aug2002, Vol. 137 Issue 1, p17 

    Provides information on a study that examined whether interferon-α plus ribavirin more effective than interferon-α alone for improving hepatitis C virologic response and liver-related morbidity and mortality in patients with chronic hepatitis C. Data sources; Study selection; Main...

  • HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C Romero-Gómez, Manuel; González-Escribano, María Francisca; Torres, Belén; Barroso, Natalia; Montes-Cano, Marco Antonio; Sánchez-Muñoz, Diego; Núñez-Roldan, Antonio; Aguilar-Reina, José // American Journal of Gastroenterology;Jul2003, Vol. 98 Issue 7, p1621 

    : ObjectiveThe aim of this study was to assess the influence of host genetic factors on response to combination therapy for chronic hepatitis C infection.: MethodsPatients with biopsy-proved chronic hepatitis C infection were treated with interferon alone (n = 143) or combined therapy of...

  • Immunological markers predicting outcome in patients with hepatitis C treated with interferon-α and ribavirin. Lee, Silvia; Macquillan, Gerry C; Keane, Niamh M; Flexman, James; Jeffrey, Gary P; French, Martyn Ah; Brochier, Jean; Price, Patricia // Immunology & Cell Biology;Aug2002, Vol. 80 Issue 4, p391 

    Summary Type 1 (T1) cytokine responses are required for the clearance of hepatitis C virus by cytotoxic T lymphocytes, but can promote liver damage. Interferon-α (IFNα) can be expected to promote T1 cytokine responses, so treatment outcome may depend on the T1/T2 cytokine environment and...

  • Interferon-α-2b Plus Ribavirin: A Review of its Use in the Management of Chronic Hepatitis C. Scott, L.J.; Perry, C.M. // Drugs;2002, Vol. 62 Issue 3, p507 

    Relatively few patients (≤20%) with chronic hepatitis C achieve a sustained virological response after interferon-α monotherapy. Hence, alternative treatment strategies such as the addition of the broad spectrum antiviral agent ribavirin to interferon-α-2b have been investigated....

  • Drugs in Development for Hepatitis C. Stauber, Rudolf E; Kessler, Harald H // Drugs;2008, Vol. 68 Issue 10, p1347 

    Currently available anti-hepatitis C virus (HCV) therapy is effective in only half of infected patients and is limited by adverse effects that often necessitate discontinuation. Therefore, new treatments are being developed, including optimization of current standard treatment with peginterferon...

  • Novel drugs in the management of difficult-to-treat hepatitis C genotypes. Cartwright, Emily J.; Miller, Lesley // Hepatic Medicine: Evidence & Research; 

    Background: Hepatitis C virus (HCV) infection is the most common chronic bloodborne infection in the United States, with approximately 3.2 million Americans being chronically infected. Rates of HCV-related end-stage liver disease and its associated morbidity and mortality have yet to peak, so...

  • Interferon affacon-1.  // Formulary;May2005, Vol. 40 Issue 5, p168 

    Reports on successful retreatment of chronic hepatitis C patients with a nonresponse to standard interferon/ribavirin using daily consensus interferon and ribavirin.

  • Modifications of the Immune Responsiveness in Patients with Hepatitis C Virus Infection following Treatment with IFN-a / Ribavirin. Caradonna, L.; Mastronardi, M.L.; Amati, L.; Magrone, T.; Cuppone, R.; Cozzolongo, R.; Manghisi, O.G.; Caccavo, D.; Amoroso, A.; Jirillo, E. // Current Pharmaceutical Design;May2002, Vol. 8 Issue 11, p981 

    The balance between T helper (h)1 and Th2 responsiveness seems to represent a key event in the evolution of hepatitis C virus (HCV) infection. In particular, Th1 cytokines [interleukin (IL-2) and interferon (IFN-?)] have been demonstrated to mediate the antiviral immune response. Serum levels of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics